NCD190.33

 

HEPATITIS PANEL/ACUTE HEPATITIS PANEL

 

Effective Date of this Version

1/1/2003

 

Benefit Category

• Diagnostic Laboratory Tests

• Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

Item/Service Description

• This panel consists of the following tests:

o Hepatitis A antibody (HAAb), IgM Antibody.

o Hepatitis B core antibody (HBcAb), IgM Antibody.

o Hepatitis B surface antigen (HBsAg).

o Hepatitis C antibody.

• Hepatitis is an inflammation of the liver resulting from viruses, drugs, toxins, and other etiologies.

o Viral hepatitis can be due to one of at least five different viruses, designated Hepatitis A, B, C, D, and E.

o Most cases are caused by:

 Hepatitis A virus (HAV).

 Hepatitis B virus (HBV).

 Hepatitis C virus (HCV).

• HAV is the most common cause of hepatitis in children and adolescents in the United States.

o Prior exposure is indicated by a positive IgG anti-HAV.

o Acute HAV is diagnosed by IgM anti-HAV, which typically appears within four weeks of exposure, and which disappears within three months of its appearance.

o IgG anti-HAV is similar in the timing of its appearance, but it persists indefinitely.

o Its detection indicates prior effective immunization or recovery from infection.

o Although HAV is spread most commonly by fecal-oral exposure, parenteral infection is possible during the acute viremia stage of the disease.

o After exposure, standard immune globulin may be effective as a prophylaxis.

• HBV produces three separate antigens (surface, core, and e (envelope) antigens) when it infects the liver, although only hepatitis B surface antigen (HBsAg) is included as part of this panel.

o Following exposure, the body normally responds by producing antibodies to each of these antigens:

 one of which is included in this panel:

 Hepatitis B surface antibody (HBsAb)-IgM antibody.

 HBsAg is the earlier marker.

 Appearing in serum four to eight weeks after exposure.

 Typically disappearing within six months after its appearance.

o If HBsAg remains detectable for greater than six months:

 This indicates chronic HBV infection.

 HBcAb, in the form of both IgG and IgM antibodies, are next to appear in serum.

 Typically becoming detectable two to three months following exposure.

o The IgM antibody gradually declines or disappears entirely one to two years following exposure, but the IgG usually remains detectable for life.

o Because HBsAg is present for a relatively short period and usually displays a low titer, a negative result does not exclude an HBV diagnosis.

o HBcAb, on the other hand, rises to a much higher titer and remains elevated for a longer period of time, but a positive result is not diagnostic of acute disease, since it may be the result of a prior infection.

o The last marker to appear in the course of a typical infection is HBsAb, which appears in serum four to six months following exposure, remains positive indefinitely, and confers immunity.

o HBV is spread exclusively by exposure to infected blood or body fluids; in the U.S., sexual transmission accounts for 30% to 60% of new cases of HBV infection.

• The diagnosis of acute HBV infection is best established by documentation of a positive IgM antibody against the core antigen (HBcAb-IgM) and by identification of a positive hepatitis B surface antigen (HBsAg).

o The diagnosis of chronic HBV infection is established primarily by identifying a positive hepatitis B surface antigen (HBsAg) and demonstrating positive IgG antibody directed against the core antigen (HBcAb-IgG).

o Additional tests such as Hepatitis B e antigen (HBeAg) and Hepatitis B e antibody (HBeAb), the envelope antigen and antibody, are NOT included in the Hepatitis Panel, but may be of importance in assessing the infectivity of patients with HBV.

o Following completion of a HBV vaccination series, HBsAb alone may be used monthly for up to six months, or until a positive result is obtained, to verify an adequate antibody response.

• HCV is the most common cause of post-transfusion hepatitis; overall HCV is responsible for 15% to 20% of all cases of acute hepatitis, and is the most common cause of chronic liver disease.

o The test most commonly used to identify HCV measures HCV antibodies, which appear in blood two to four months after infection. False positive HCV results can occur.

o For example, a patient with a recent yeast infection may produce a false positive anti-HCV result.

o For this reason, at present positive results usually are confirmed by a more specific technique.

o Like HBV, HCV is spread exclusively through exposure to infected blood or body fluids.

• This panel of tests is used for differential diagnosis in a patient with symptoms of liver disease or injury.

o When the time of exposure or the stage of the disease is not known, a patient with continued symptoms of liver disease despite a completely negative Hepatitis Panel may need a repeat panel approximately two weeks to two months later to exclude the possibility of hepatitis.

o Once a diagnosis is established, specific tests can be used to monitor the course of the disease.

 

Indications and Limitations of Coverage

 

Indications

1. To detect viral hepatitis infection when there are abnormal liver function test results, with or without signs or symptoms of hepatitis.

2. Prior to and subsequent to liver transplantation.

Limitations

• After a hepatitis diagnosis has been established, only individual tests, rather than the entire panel, are needed.

• Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

 

Cross Reference

• Also see the Medicare Claims Processing Manual, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

 

Coverage Transmittal Link

• http://www.cms.gov/transmittals/downloads/R17NCD.pdf

 

Other

Covered Code Lists (including narrative)

• January 2013

October 2012

July 2012

April 2012

January 2012

October 2011

July 2011

April 2011

January 2011

October 2010

July 2010

April 2010

January 2010

October 2009

July 2009

April 2009

January 2009

October 2008

July 2008

April 2007

January 2007

 

Changes to Lab NCD Edit Software

• January 2012

October 2011

January 2011

October 2010

July 2010

October 2009

July 2009

January 2009

October 2008

July 2008

April 2007

January 2007

October 2006

July 2006

April 2006

January 2006

October 2005

July 2005

April 2005

January 2005

October 2004

July 2004

April 2004

January 2004

October 2003

July 2003

April 2003

 

Coding Analyses for Labs (CALs)

• This NCD has been or is currently being reviewed under the National Coverage Determination process.

• The following are existing associations with CALs, from the Coding Analyses for Labs database.

• Original consideration for Hepatitis Panel (Removal of ICD-9-CM Code 784.69, Other symbolic dysfunction, from the list of Codes Covered by Medicare) (CAG-00283N)

• Original consideration for Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.4, Elevation of Levels of Transaminase or Lactic Acid Dehydrogenase) (CAG-00304N)

• Original consideration for Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.5, Other nonspecific abnormal serum enzyme levels, as a covered indication) (CAG-00335N)

 

Medicare NCD Link